Calcineurin inhibitors ± steroids vs placebo/no treatment/supportive treatment/steroids
Adverse events ‐ malignancy at 36 months · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 2.79 [0.14, 56.57]1 study · 107 participantsVery low